Molecular tumour board review
Authoring and signing every Blueprint Care decision.
If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest: solid tumour
All Signature testsEvery panel compared, side by sideSignature STb33 genes from a blood drawSignature STb O118 genes from blood, including fusionsSignature STb O+523 genes, with TMB, MSI and pharmacogenomicsSignature STt OComprehensive profiling from a tissue blockTest: blood cancer
Signature BML+Myeloid, 600+ genes, with MDS and MPN overlapSignature BLL+Lymphoid, 600+ genes, with Philadelphia-like detectionSignature CustomDesigned around one question when neither family fitsMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillance for solid tumoursClear BloodResidual disease surveillance after blood cancer treatmentProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedJourneysFour composites showing how a decision gets madeCase studiesNine situations and the test that fits eachFAQThe questions we are asked mostCompany · our exclusive clinical partner
Where OnKommon was born, and the licensed clinical authority behind everything we deliver.
Who KPCIRC is
KPCIRC, the Kwatra Precision Cancer Institute and Research Centre, is where OnKommon was born and the licensed clinical authority behind everything we deliver.
Authoring and signing every Blueprint Care decision.
Independent clinical review on a paid basis, whenever you want one.
Before and after inherited-risk testing.
The human coordination that carries a plan into action.
Acting on Sentinel and Clear findings as they arrive.
Not a marketplace of interchangeable labs and signatories.
OnKommon and KPCIRC are exclusive to each other. One accountable clinical partner whose judgement stands behind every report. That exclusivity is what lets us promise a named, consistent standard of care across the whole ecosystem.
Every patient and every doctor asks the same two questions of any precision-oncology service: who is clinically responsible, and is a machine making the decision?
A licensed clinical team at KPCIRC, named and accountable.
No. Our technology informs them. They decide.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal